Skip to main content

People in the News: Dec 21, 2010

Premium

Med BioGene has named Scott Davis to replace David Matthews as chief financial officer. Davis is a partner of Cross Davis & Company, an accounting and management contract services company.


Epigenomics' Chief Financial Officer Oliver Schacht plans to leave the company in March 2011. The company said that it has reached an agreement to hire an "experienced" CFO, whose name the firm will release in January due to confidentiality obligations, to take over the post in April. The company also plans to recruit a new US-based marketing and sales executive to lead its US operations, which are currently run by Schacht.


HistoRx has appointed Jack Davis to serve on its board of directors. Davis is the former President and CEO of Dianon Systems, which was bought by Laboratory Corporation of America in 2002. He also has served as CEO of Calypte Biomedical and worldwide general manager of Abbott Laboratories' Diagnostics Products business.


Rosetta Genomics said this week that Brian Markison has become an observer to the company's board of directors and, upon shareholder approval, will become a director. Markison is chairman and CEO of King Pharmaceuticals and led the company through to its recently announced acquisition by Pfizer. Before that, he was with Bristol-Myers Squibb.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.